<code id='3C15ED9077'></code><style id='3C15ED9077'></style>
    • <acronym id='3C15ED9077'></acronym>
      <center id='3C15ED9077'><center id='3C15ED9077'><tfoot id='3C15ED9077'></tfoot></center><abbr id='3C15ED9077'><dir id='3C15ED9077'><tfoot id='3C15ED9077'></tfoot><noframes id='3C15ED9077'>

    • <optgroup id='3C15ED9077'><strike id='3C15ED9077'><sup id='3C15ED9077'></sup></strike><code id='3C15ED9077'></code></optgroup>
        1. <b id='3C15ED9077'><label id='3C15ED9077'><select id='3C15ED9077'><dt id='3C15ED9077'><span id='3C15ED9077'></span></dt></select></label></b><u id='3C15ED9077'></u>
          <i id='3C15ED9077'><strike id='3C15ED9077'><tt id='3C15ED9077'><pre id='3C15ED9077'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:comprehensive    Page View:9361

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In